Reviews Cisatracurium Besylate


No reviews yet.

Nimbex Drug Description
Nimbex® Injection
(cisatracurium besylate)
This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards.
DRUG DESCRIPTION



What are the possible side effects of cisatracurium (Nimbex)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

slow heart rate;
noisy breathing, feeling short of breath;
ongoing muscle weakness; or
inability to move your muscles.

Less serious side effects may include:

feeling light-headed;
...
Read All Potential Side Effects for Nimbex »




NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant
for intravenous administration. Compared to other neuromuscular blocking agents,
it is intermediate in its onset and duration of action. Cisatracurium besylate
is one of 10 isomers of atracurium besylate and constitutes approximately 15%
of that mixture. Cisatracurium besylate is [1R- [1α,2α(1'
R*,2'R*)]]-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate. The molecular
formula of the cisatracurium parent biscation is C53H72N2O12
and the molecular weight is 929.2. The molecular formula of cisatracurium as
the besylate salt is C65H82N2O18S2
and the molecular weight is 1243.50. The structural formula of cisatracurium
besylate is:







The log of the partition coefficient of cisatracurium besylate is -2.12 in a 1-octanol/distilled water system at 25°C.
NIMBEX Injection is a sterile, non-pyrogenic aqueous solution provided in 5
mL, 10 mL, and 20 mL vials. The pH is adjusted to 3.25 to 3.65 with benzenesulfonic
acid. The 5 mL and 10 mL vials each contain cisatracurium besylate, equivalent
to 2 mg/mL cisatracurium. The 20 mL vial, intended for ICU use only,
contains cisatracurium besylate, equivalent to 10 mg/mL cisatracurium. The 10
mL vial, intended for multiple-dose use, contains 0.9% benzyl alcohol as a preservative.
The 5 mL and 20 mL vials are single-use vials and do not contain benzyl alcohol.
Cisatracurium besylate slowly loses potency with time at a rate of approximately
5% per year under refrigeration (5°C). NIMBEX should be refrigerated at
2° to 8°C (36° to 46°F) in the carton to preserve potency. The
rate of loss in potency increases to approximately 5% per month at 25°C
(77°F). Upon removal from refrigeration to room temperature storage conditions
(25°C/77°F), use NIMBEX within 21 days, even if rerefrigerated.Last reviewed on RxList: 5/23/2008




Nimbex Drug Description
Nimbex® Injection
(cisatracurium besylate)
This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards.
DRUG DESCRIPTION



What are the possible side effects of cisatracurium (Nimbex)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

slow heart rate;
noisy breathing, feeling short of breath;
ongoing muscle weakness; or
inability to move your muscles.

Less serious side effects may include:

feeling light-headed;
...
Read All Potential Side Effects for Nimbex »




NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant
for intravenous administration. Compared to other neuromuscular blocking agents,
it is intermediate in its onset and duration of action. Cisatracurium besylate
is one of 10 isomers of atracurium besylate and constitutes approximately 15%
of that mixture. Cisatracurium besylate is [1R- [1α,2α(1'
R*,2'R*)]]-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate. The molecular
formula of the cisatracurium parent biscation is C53H72N2O12
and the molecular weight is 929.2. The molecular formula of cisatracurium as
the besylate salt is C65H82N2O18S2
and the molecular weight is 1243.50. The structural formula of cisatracurium
besylate is:







The log of the partition coefficient of cisatracurium besylate is -2.12 in a 1-octanol/distilled water system at 25°C.
NIMBEX Injection is a sterile, non-pyrogenic aqueous solution provided in 5
mL, 10 mL, and 20 mL vials. The pH is adjusted to 3.25 to 3.65 with benzenesulfonic
acid. The 5 mL and 10 mL vials each contain cisatracurium besylate, equivalent
to 2 mg/mL cisatracurium. The 20 mL vial, intended for ICU use only,
contains cisatracurium besylate, equivalent to 10 mg/mL cisatracurium. The 10
mL vial, intended for multiple-dose use, contains 0.9% benzyl alcohol as a preservative.
The 5 mL and 20 mL vials are single-use vials and do not contain benzyl alcohol.
Cisatracurium besylate slowly loses potency with time at a rate of approximately
5% per year under refrigeration (5°C). NIMBEX should be refrigerated at
2° to 8°C (36° to 46°F) in the carton to preserve potency. The
rate of loss in potency increases to approximately 5% per month at 25°C
(77°F). Upon removal from refrigeration to room temperature storage conditions
(25°C/77°F), use NIMBEX within 21 days, even if rerefrigerated.Last reviewed on RxList: 5/23/2008




Nimbex Drug Description
Nimbex® Injection
(cisatracurium besylate)
This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards.
DRUG DESCRIPTION



What are the possible side effects of cisatracurium (Nimbex)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

slow heart rate;
noisy breathing, feeling short of breath;
ongoing muscle weakness; or
inability to move your muscles.

Less serious side effects may include:

feeling light-headed;
...
Read All Potential Side Effects for Nimbex »




NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant
for intravenous administration. Compared to other neuromuscular blocking agents,
it is intermediate in its onset and duration of action. Cisatracurium besylate
is one of 10 isomers of atracurium besylate and constitutes approximately 15%
of that mixture. Cisatracurium besylate is [1R- [1α,2α(1'
R*,2'R*)]]-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate. The molecular
formula of the cisatracurium parent biscation is C53H72N2O12
and the molecular weight is 929.2. The molecular formula of cisatracurium as
the besylate salt is C65H82N2O18S2
and the molecular weight is 1243.50. The structural formula of cisatracurium
besylate is:







The log of the partition coefficient of cisatracurium besylate is -2.12 in a 1-octanol/distilled water system at 25°C.
NIMBEX Injection is a sterile, non-pyrogenic aqueous solution provided in 5
mL, 10 mL, and 20 mL vials. The pH is adjusted to 3.25 to 3.65 with benzenesulfonic
acid. The 5 mL and 10 mL vials each contain cisatracurium besylate, equivalent
to 2 mg/mL cisatracurium. The 20 mL vial, intended for ICU use only,
contains cisatracurium besylate, equivalent to 10 mg/mL cisatracurium. The 10
mL vial, intended for multiple-dose use, contains 0.9% benzyl alcohol as a preservative.
The 5 mL and 20 mL vials are single-use vials and do not contain benzyl alcohol.
Cisatracurium besylate slowly loses potency with time at a rate of approximately
5% per year under refrigeration (5°C). NIMBEX should be refrigerated at
2° to 8°C (36° to 46°F) in the carton to preserve potency. The
rate of loss in potency increases to approximately 5% per month at 25°C
(77°F). Upon removal from refrigeration to room temperature storage conditions
(25°C/77°F), use NIMBEX within 21 days, even if rerefrigerated.Last reviewed on RxList: 5/23/2008




Nimbex Drug Description
Nimbex® Injection
(cisatracurium besylate)
This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards.
DRUG DESCRIPTION



What are the possible side effects of cisatracurium (Nimbex)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

slow heart rate;
noisy breathing, feeling short of breath;
ongoing muscle weakness; or
inability to move your muscles.

Less serious side effects may include:

feeling light-headed;
...
Read All Potential Side Effects for Nimbex »




NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant
for intravenous administration. Compared to other neuromuscular blocking agents,
it is intermediate in its onset and duration of action. Cisatracurium besylate
is one of 10 isomers of atracurium besylate and constitutes approximately 15%
of that mixture. Cisatracurium besylate is [1R- [1α,2α(1'
R*,2'R*)]]-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate. The molecular
formula of the cisatracurium parent biscation is C53H72N2O12
and the molecular weight is 929.2. The molecular formula of cisatracurium as
the besylate salt is C65H82N2O18S2
and the molecular weight is 1243.50. The structural formula of cisatracurium
besylate is:







The log of the partition coefficient of cisatracurium besylate is -2.12 in a 1-octanol/distilled water system at 25°C.
NIMBEX Injection is a sterile, non-pyrogenic aqueous solution provided in 5
mL, 10 mL, and 20 mL vials. The pH is adjusted to 3.25 to 3.65 with benzenesulfonic
acid. The 5 mL and 10 mL vials each contain cisatracurium besylate, equivalent
to 2 mg/mL cisatracurium. The 20 mL vial, intended for ICU use only,
contains cisatracurium besylate, equivalent to 10 mg/mL cisatracurium. The 10
mL vial, intended for multiple-dose use, contains 0.9% benzyl alcohol as a preservative.
The 5 mL and 20 mL vials are single-use vials and do not contain benzyl alcohol.
Cisatracurium besylate slowly loses potency with time at a rate of approximately
5% per year under refrigeration (5°C). NIMBEX should be refrigerated at
2° to 8°C (36° to 46°F) in the carton to preserve potency. The
rate of loss in potency increases to approximately 5% per month at 25°C
(77°F). Upon removal from refrigeration to room temperature storage conditions
(25°C/77°F), use NIMBEX within 21 days, even if rerefrigerated.Last reviewed on RxList: 5/23/2008




Nimbex Drug Description
Nimbex® Injection
(cisatracurium besylate)
This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards.
DRUG DESCRIPTION



What are the possible side effects of cisatracurium (Nimbex)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

slow heart rate;
noisy breathing, feeling short of breath;
ongoing muscle weakness; or
inability to move your muscles.

Less serious side effects may include:

feeling light-headed;
...
Read All Potential Side Effects for Nimbex »




NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant
for intravenous administration. Compared to other neuromuscular blocking agents,
it is intermediate in its onset and duration of action. Cisatracurium besylate
is one of 10 isomers of atracurium besylate and constitutes approximately 15%
of that mixture. Cisatracurium besylate is [1R- [1α,2α(1'
R*,2'R*)]]-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate. The molecular
formula of the cisatracurium parent biscation is C53H72N2O12
and the molecular weight is 929.2. The molecular formula of cisatracurium as
the besylate salt is C65H82N2O18S2
and the molecular weight is 1243.50. The structural formula of cisatracurium
besylate is:







The log of the partition coefficient of cisatracurium besylate is -2.12 in a 1-octanol/distilled water system at 25°C.
NIMBEX Injection is a sterile, non-pyrogenic aqueous solution provided in 5
mL, 10 mL, and 20 mL vials. The pH is adjusted to 3.25 to 3.65 with benzenesulfonic
acid. The 5 mL and 10 mL vials each contain cisatracurium besylate, equivalent
to 2 mg/mL cisatracurium. The 20 mL vial, intended for ICU use only,
contains cisatracurium besylate, equivalent to 10 mg/mL cisatracurium. The 10
mL vial, intended for multiple-dose use, contains 0.9% benzyl alcohol as a preservative.
The 5 mL and 20 mL vials are single-use vials and do not contain benzyl alcohol.
Cisatracurium besylate slowly loses potency with time at a rate of approximately
5% per year under refrigeration (5°C). NIMBEX should be refrigerated at
2° to 8°C (36° to 46°F) in the carton to preserve potency. The
rate of loss in potency increases to approximately 5% per month at 25°C
(77°F). Upon removal from refrigeration to room temperature storage conditions
(25°C/77°F), use NIMBEX within 21 days, even if rerefrigerated.Last reviewed on RxList: 5/23/2008





Other reviews about Cisatracurium Besylate on web:

Cisatracurium (formerly recognized as 51W89, and marketed as Nimbex ™) is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular ... Cisatracurium besilate - Wikipedia, the free encyclopedia


Learn about the prescription medication Nimbex (Cisatracurium Besylate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Nimbex (Cisatracurium Besylate) Drug Information: Uses, Side ...


Teva Active Pharmaceutical Ingredients ( TAPI) is a leading international supplier of Active Pharmaceutical Ingredients for generic and innovative companies. Cisatracurium Besylate - TEVA API


Cisatracurium Besylate professional patient advice. Specific and up to date information about Cisatracurium Besylate. Complete Cisatracurium Besylate information from Drugs.com


Cisatracurium, an isomer of atracurium besylate is a nondepolarizing skeletal muscle relaxant. It competes for cholinergic receptors at the motor end plate. MedicineHouse.com


Cisatracurium besylate is a neuromuscular blocking agent. Cisatracurium besylate is indicated for use during surgical and other procedures and in intensive care. Cisatracurium Besylate


Resource URI: http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00565 Cisatracurium Besylate | D2R Server publishing the DrugBank ...


NIMBEX SUMMARY NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents ... Nimbex (Cisatracurium) - Drug Info, Side Effects, Research ...


Nimbex (cisatracurium besylate) Product information specific to a particular country is available at the Web site(s ... Nimbex


Cisatracurium. University Health Care System, Augusta, CSRA, GA, SC - Cisatracurium Besylate Generic Available: No Canadian Brand Names: Nimbex(r) Use: Adjunct to general ... Augusta Health - Cisatracurium. Cisatracurium Besylate Generic ...





Featured Reviews

Reviews Magnevist

Magnevist Drug Description MAGNEVIST® (gadopentetate dimeglumine) Injection FOR INTRAVENOUS ADMINISTRATION WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis...
Read More  |  Review This
Reviews Metrogel

Metrogel Drug Description METROGEL® (metronidazole) Gel, 1% For topical use only. DRUG DESCRIPTION What are the possible side effects of metronidazole topical (MetroCream, MetroGel, MetroLotion, Noritate)? Get emergency medical...
Read More  |  Review This
Reviews Sodium Polystyrene

Kayexalate Drug Description Kayexalate® (sodium polystyrene sulfonate, USP) Cation-Exchange Resin DRUG DESCRIPTION What are the possible side effects of sodium polystyrene sulfonate (Kayexalate, Kionex)? Get emergency medical...
Read More  |  Review This
Reviews Xifaxan

Xifaxan Drug Description XIFAXAN (rifaximin) Tablets DRUG DESCRIPTION What are the possible side effects of rifaximin (Xifaxan)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Zolpidem Tartrate Oral Spray

Zolpimist Drug Description Zolpimist (zolpidem tartrate) Oral Spray DRUG DESCRIPTION Zolpimist contains zolpidem tartrate, a non-benzodiazepine hypnotic of the imidazopyridine class. Chemically, zolpidem is N,N,6-trimethyl-2-p-tolylimidazo[1,2-a] ...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....